These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24340637)

  • 41. Regulatory Oversight of Cell- and Tissue-Based Therapeutic Products and Gene Therapy Products in Singapore.
    Goh CW; Kellathur SN; Ong LL; Wu X
    Adv Exp Med Biol; 2015; 871():195-212. PubMed ID: 26374220
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulatory considerations for the development of autologous induced pluripotent stem cell therapies.
    Carpenter MK; Couture LA
    Regen Med; 2010 Jul; 5(4):569-79. PubMed ID: 20632860
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phage Therapy Regulation: From Night to Dawn.
    Fauconnier A
    Viruses; 2019 Apr; 11(4):. PubMed ID: 30999559
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Legal basis of the Advanced Therapies Regulation.
    Jekerle V; Schröder C; Pedone E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):4-8. PubMed ID: 19940965
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Standards for humidification and filtration devices.
    Stevens J
    Respir Care Clin N Am; 2006 Jun; 12(2):203-32. PubMed ID: 16828691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Regulation (EC) No. 1394/2007 on advanced therapy medicinal products : Incorporation into national law].
    Dwenger A; Strassburger J; Schwerdtfeger W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):14-9. PubMed ID: 20033662
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice.
    International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use.
    J Postgrad Med; 2001; 47(1):45-50. PubMed ID: 11590294
    [No Abstract]   [Full Text] [Related]  

  • 49. Design and international harmonization of pharmacopoeial standards.
    Calam DH
    J Pharm Biomed Anal; 1995 Dec; 14(1-2):1-5. PubMed ID: 8833960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United States.
    Rauws AG; Groen K
    Chirality; 1994; 6(2):72-5. PubMed ID: 8204416
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulatory forum opinion piece*: supporting the need for international harmonization of safety assessments for food flavoring substances.
    Konishi Y; Hayashi SM; Fukushima S
    Toxicol Pathol; 2014 Aug; 42(6):949-53. PubMed ID: 23881932
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regulatory enablers and regulatory challenges for the development of tissue-engineered products in the EU.
    Brévignon-Dodin L
    Biomed Mater Eng; 2010; 20(3):121-6. PubMed ID: 20930319
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Harmonisation of regulatory requirements for clinical trials on medicinal products for human use in the Directive 2001/20/EC and complementary guidance. Implementation of the 12th Law Amending the German Drug Law].
    Geisler I; Hofmann HP; Nickel L
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):141-6. PubMed ID: 15726454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. JACIE accreditation in 2008: demonstrating excellence in stem cell transplantation.
    Pamphilon D; Apperley JF; Samson D; Slaper-Cortenbach I; McGrath E
    Hematol Oncol Stem Cell Ther; 2009; 2(2):311-9. PubMed ID: 20118054
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulatory requirements for clinical trial and marketing authorisation application for cell-based medicinal products.
    Salmikangas P; Flory E; Reinhardt J; Hinz T; Maciulaitis R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):24-9. PubMed ID: 19940964
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulatory aspects of cellular therapy product in Europe: JACIE accreditation in a processing facility.
    Caunday O; Bensoussan D; Decot V; Bordigoni P; Stoltz JF
    Biomed Mater Eng; 2009; 19(4-5):373-9. PubMed ID: 20042804
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Marketing authorization of veterinary medicinal products in Poland.
    Sztabińska-Koncka H; Lewicki J
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):129-33. PubMed ID: 9339489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What can be learnt from the Japanese regulatory approach to tissue engineered products?
    Brévignon-Dodin L; Livesey F
    Regen Med; 2007 Nov; 2(6):967-71. PubMed ID: 18034634
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Canadian Regulatory Framework and Regulatory Requirements for Cell and Gene Therapy Products.
    Wang J; Griffiths E; Tounekti O; Nemec M; Deneault E; Lavoie JR; Ridgway A
    Adv Exp Med Biol; 2023; 1430():91-116. PubMed ID: 37526844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.